YMAB fundamentals
Key facts
Market capitalization224.28 MUSD
Basic EPS (TTM)−0.67USD
Founded2015
CEOMichael Rossi
Websiteymabs.com
About
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−44%
−34%
−24%
−14%
−4%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−10.00 M
0.00
10.00 M
20.00 M
30.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
YMAB does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company